Osteonecrosis of the jaw related to sunitinib

Oral Maxillofac Surg. 2011 Mar;15(1):63-6. doi: 10.1007/s10006-010-0224-y.

Abstract

Case report: A 59-year-old male patient was referred to the hospital with exposed bone measuring 10 mm in diameter in the posterior, left-side region of the lower jaw. Two months previous, the first molar had been extracted. The patient had contracted renal cell carcinoma and had been treated by nephrectomy in 2003. Soft tissue metastases occurred. After initial therapy with interferon and vinblastine, a relapse occurred and the therapy was changed to sorafenib, followed by sunitinib. Osteonecrosis of the lower jaw appeared 1 year after initial and exclusive therapy with sunitinib.

Conclusions: Bisphosphonates had never been applied. With increasing application of multi-kinase inhibitors, complications due to osteonecrosis could occur more frequently.

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / surgery
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Humans
  • Indoles / adverse effects*
  • Indoles / therapeutic use
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / surgery
  • Male
  • Mandibular Diseases / chemically induced*
  • Mandibular Diseases / diagnosis
  • Mandibular Diseases / surgery
  • Middle Aged
  • Molar / surgery
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / surgery
  • Nephrectomy
  • Osteonecrosis / chemically induced*
  • Osteonecrosis / diagnosis
  • Osteonecrosis / surgery
  • Postoperative Complications / chemically induced
  • Postoperative Complications / diagnosis
  • Postoperative Complications / surgery
  • Pyrroles / adverse effects*
  • Pyrroles / therapeutic use
  • Sunitinib
  • Tooth Extraction

Substances

  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib